Literature DB >> 17229653

Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.

Arne Kolstad, Harald Holte, Alexander Fosså, Grete Fossum Lauritzsen, Peter Gaustad, Dag Torfoss.   

Abstract

We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17229653     DOI： 10.3324/haematol.10564

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  24 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

Review 2.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

3.  Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review.

Authors:  Xu-Qin Jiang; Lei Fang; Xiao-Dong Mei; Xiao-Jing Wang; Ming-Hong Bao
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 4.  Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.

Authors:  Pieternella J Lugtenburg; Pieter Sonneveld
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

5.  B Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of Pneumocystis Infection in Mice.

Authors:  Michael M Opata; Melissa L Hollifield; Frances E Lund; Troy D Randall; Robert Dunn; Beth A Garvy; David J Feola
Journal:  J Immunol       Date:  2015-06-03       Impact factor: 5.422

6.  Pneumocystis pneumonia in patients treated with rituximab.

Authors:  Isabel Martin-Garrido; Eva M Carmona; Ulrich Specks; Andrew H Limper
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

7.  Glycosphingolipids mediate pneumocystis cell wall β-glucan activation of the IL-23/IL-17 axis in human dendritic cells.

Authors:  Eva M Carmona; Theodore J Kottom; Deanne M Hebrink; Teng Moua; Raman-Deep Singh; Richard E Pagano; Andrew H Limper
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-16       Impact factor: 6.914

Review 8.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

9.  Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab.

Authors:  Sean Warsch; Peter J Hosein; Michele I Morris; Uygar Teomete; Ronald Benveniste; Jennifer R Chapman; Izidore S Lossos
Journal:  Int J Hematol       Date:  2012-06-09       Impact factor: 2.490

10.  Increased incidence of interstitial pneumonia by CHOP combined with rituximab.

Authors:  Daisuke Ennishi; Yasuhito Terui; Masahiro Yokoyama; Yuko Mishima; Shunji Takahashi; Kengo Takeuchi; Kazuma Ikeda; Mitsune Tanimoto; Kiyohiko Hatake
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.